The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 16, 2010
Filed:
Jan. 30, 2003
Hans-ulrich Petereit, Darmstadt, DE;
Thomas Suefke, Erzhausen, DE;
Christian Meier, Darmstadt, DE;
Michael Schnabel, Biebesheim, DE;
Ingrid Blesing, Fuerth/Odenwald, DE;
Stefan Grimm, Wintersheim, DE;
Hans-Ulrich Petereit, Darmstadt, DE;
Thomas Suefke, Erzhausen, DE;
Christian Meier, Darmstadt, DE;
Michael Schnabel, Biebesheim, DE;
Ingrid Blesing, Fuerth/Odenwald, DE;
Stefan Grimm, Wintersheim, DE;
Evonik Roehm GmbH, Darmstadt, DE;
Abstract
The invention relates to a method for producing a pharmaceutical dosage form as tablets, pellets and/or in the form of an active ingredient-containing matrix, whereby the tablets, pellets and/or active ingredient-containing matrix contain a pharmaceutical active ingredient and a copolymer serving as a coating agent and/or binding agent, and optionally contain a core and pharmaceutically common additives. According to the invention, the copolymer, the pharmaceutical active ingredient, the optionally present core and/or the pharmaceutically common additives are processed using known techniques by melting, injection molding, extrusion, wet granulation, casting, dipping, spreading out, spraying on, or pressing to form tablets, pellets and/or an active ingredient-containing matrix. The inventive method is characterized in that a copolymer is used that consists of 20 to 34 wt. % methacrylic acid, 20 to 69 wt. % methylacrylate and 0 to 40 wt. % ethylacrylate and, optionally, of 0 to 10 wt. % of additional vinylically copolymerizable monomers with the provision that the glass transition temperature of the copolymer is no higher than 60° C. according to ISO 11357-2, Item 3.3.3. The invention also relates to the pharmaceutical dosage form produced according to this method, said copolymer and the use thereof.